Journal of the American Academy of Dermatology
Volume 58, Issue 5 , Pages 851-864 , May 2008

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

  • Alice Gottlieb, MD, PhD

      Affiliations

    • Department of Dermatology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Neil J. Korman, MD, PhD

      Affiliations

    • Murdough Family Center For Psoriasis, Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Kenneth B. Gordon, MD

      Affiliations

    • Division of Dermatology, Evanston Northwestern Healthcare and Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Steven R. Feldman, MD, PhD

      Affiliations

    • Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Mark Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York, New York
    • ,
  • John Y.M. Koo, MD

      Affiliations

    • Department of Dermatology, University of California–San Francisco, San Francisco, California
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Craig A. Elmets, MD

      Affiliations

    • University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Craig L. Leonardi, MD

      Affiliations

    • Department of Dermatology, Saint Louis University, Saint Louis, Missouri
    • ,
  • Karl R. Beutner, MD, PhD

      Affiliations

    • Anacor Pharmaceuticals Inc, Palo Alto, California
    • ,
  • Reva Bhushan, PhD

      Affiliations

    • American Academy of Dermatology, Schaumburg, Illinois
    • Corresponding Author InformationReprint requests: Reva Bhushan, PhD, 930 E Woodfield Rd, Schaumburg, IL 60173.
    • ,
  • Alan Menter, MD, Chair

      Affiliations

    • Baylor University Medical Center, Dallas, Texas

References 

  1. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman JL, Ewigman B, et al. Simplifying the language of evidence to improve patient care: strength of recommendation taxonomy (SORT); a patient-centered approach to grading evidence in medical literature. J Fam Pract. 2004;53:111–120
  2. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573
  3. Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study. J Dermatol Treat. 2006;17:343–352
  4. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247–1250
  5. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity?. Ann Rheum Dis. 2005;64:188–190
  6. Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford). 2007;46:417–425
  7. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–831
  8. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis. 2003;62:68–70
  9. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78
  10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673
  11. Helliwell PS, Porter G, Taylor WJ. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113–117
  12. Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: magnetic resonance imaging and x-ray findings. Acta Derm Venereol. 1998;78:463–465
  13. Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Ann Rheum Dis. 2005;64(Suppl):ii55–ii57
  14. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65:478–481
  15. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis–a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46:253–256
  16. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004;50:24–35
  17. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385–390
  18. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl):ii49–ii54
  19. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685–704
  20. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64(Suppl):ii74–ii77
  21. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964;189:743–747
  22. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376–381
  23. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A Department of Veterans Affairs cooperative study. Arthritis Rheum. 1996;39:2013–2020
  24. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939–1950
  25. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157
  26. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289
  27. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272
  28. Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmd EB, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol. 2007;6:299–306
  29. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581–587
  30. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518–523
  31. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–488
  32. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721
  33. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043
  34. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638–1645

 Funding sources: None.

 Conflicts of interest: The authors' conflict of interest/disclosure statements appear at the end of the article.

PII: S0190-9622(08)00274-0

doi: 10.1016/j.jaad.2008.02.040

Journal of the American Academy of Dermatology
Volume 58, Issue 5 , Pages 851-864 , May 2008

Article Tools

* Image Usage & Resolution